Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

This update covers current health news, focusing on Parvus Asset Management's influence on Novo Nordisk's CEO selection, ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

--Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief executive following a share-price slump, according to the ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

FILE PHOTO: A person walks near the Milan Bourse (Italian stock exchange) as global markets brace for a hit to trade and ...